Detection of occult metastases in sentinel lymph nodes from colon cancer patients by K-ras mutation peptide nucleic acid clamp PCR

Annals of Surgery

Volumn 251, Issue 6, 2010, Pages 1087-1091

  Oltedal, Satu ^a   Gilje, Bjørnar ^b   Kørner, Hartwig ^a,c   Aasprong, Ole Gunnar ^a   Tjensvoll, Kjersti ^a   Heikkilä, Reino ^b   Smaaland, Rune ^a,b   Nordgård, Oddmund ^a,b  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b Departments of Hematology and Oncology   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN;

ADULT; AGED; ARTICLE; COLON CANCER; CONTROLLED STUDY; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; SENTINEL LYMPH NODE;

ADENOCARCINOMA; CELL LINE, TUMOR; COLONIC NEOPLASMS; GENES, RAS; HUMANS; LYMPHATIC METASTASIS; MUTATION; PEPTIDE NUCLEIC ACIDS; POLYMERASE CHAIN REACTION; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 77953021664     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181dae1bc     Document Type: Article

References (29)

1. Greene FL, Page DI, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002
2. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet. 1995;345:939-944.
3. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96:1420-1425.
4. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322: 352-358.
5. Benson AB III, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22:3408-3419.
6. Figueredo A, Charette ML, Maroun J, et al. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol. 2004;22:3395-3407.
7. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22:1797-1806.
8. Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroen-terology. 2008;134:1296-1310.
9. Nicastri DG, Doucette JT, Godfrey TE, et al. Is occult lymph node disease in colorectal cancer patients clinically significant? A review of the relevant literature. J Mol Diagn. 2007;9:563-571.
10. Nordgård O, Kørner H, Aasprong OG, et al. Sentinel lymph nodes in colorectal cancer. Tidsskr Nor Laegeforen. 2007;127:2829-2833.
11. de Haas RJ, Wicherts DA, Hobbelink MG, et al. Sentinel lymph node mapping in colon cancer: current status. Ann Surg Oncol. 2007;14:1070-1080.
12. Des Guetz G, Uzzan B, Nicolas P, et al. Is sentinel lymph node mapping in colorectal cancer a future prognostic factor? A meta-analysis. World J Surg. 2007;31:1304-1312.
13. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392-399.
14. Nordgård O, Oltedal S, Kørner H, et al. Quantitative RT-PCR detection of tumor cells in sentinel lymph nodes isolated from colon cancer patients with an ex vivo approach. Ann Surg. 2009;249:602-607.
15. Luchtenborg M, Weijenberg MP, Wark PA, et al. Mutations in APC, CTNNB1 and K-ras genes and expression of hMLH1 in sporadic colorectal carcinomas from the Netherlands Cohort study. BMC Cancer. 2005;5:160.
16. Chang SC, Lin JK, Yang SH, et al. Relationship between genetic alterations and prognosis in sporadic colorectal cancer. Int J Cancer. 2006;118:1721-1727.
17. Wang JY, Wang YH, Jao SW, et al. Molecular mechanisms underlying the tumorigenesis of colorectal adenomas: correlation to activated K-ras onco-gene. Oncol Rep. 2006;16:1245-1252.
18. Calistri D, Rengucci C, Seymour I, et al. Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression. J Cell Physiol. 2005;204:484-488.
19. Dabritz J, Hanfler J, Preston R, et al. Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes. Br J Cancer. 2005;92:405-412.
20. Hayashi N, Arakawa H, Nagase H, et al. Genetic diagnosis identifies occult lymph node metastases undetectable by the histopathological method. Cancer Res. 1994;54:3853-3856.
21. Hayashi N, Ito I, Yanagisawa A, et al. Genetic diagnosis of lymph-node metastasis in colorectal cancer. Lancet. 1995;345:1257-1259.
22. Taback B, Bilchik AJ, Saha S, et al. Peptide nucleic acid clamp PCR: a novel K-ras mutation detection assay for colorectal cancer micrometastases in lymph nodes. Int J Cancer. 2004;111:409-414.
23. Gilje B, Heikkilä R, Oltedal S, et al. High-fidelity DNA polymerase enhances the sensitivity of a peptide nucleic acid clamp PCR assay for K-ras mutations. J Mol Diagn. 2008;10:325-331.
24. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49: 4682-4689.
25. Dieterle CP, Conzelmann M, Linnemann U, et al. Detection of isolated tumor cells by polymerase chain reaction-restriction fragment length polymorphism for K-ras mutations in tissue samples of 199 colorectal cancer patients. Clin Cancer Res. 2004;10:641-650.
26. Santini D, Loupakis F, Vincenzi B, et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist. 2008;13:1270-1275.
27. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-1634.
28. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst. 1998;90:675-684.
29. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359: 1757-1765.